logo-loader
viewAstraZeneca

AstraZeneca sells rights to high cholesterol treatment for up to US$350mln

Germany's Grünenthal will be able to sell Crestor in over 30 countries in Europe, except the UK and Spain

AstraZeneca - AstraZeneca sells rights to high cholesterol treatment for up to US$350mln

AstraZeneca PLC (LON:AZN) announced it has agreed to sell the rights to Crestor and associated medicines in over 30 countries in Europe, except the UK and Spain, to Grünenthal. 

Crestor is a statin approved for the treatment of dyslipidaemia, in which disrupted metabolism leads to changes of fats in the blood, and high cholesterol. 

READ: AstraZeneca gets upgrade from UBS but 2021 "won't be plain sailing" 

As part of the agreement, the German firm will make an initial payment of US$320mln followed by future milestone payments of up to US$30mln. 

The divestment is anticipated to close in the first quarter of 2021, the FTSE 100 firm said. 

AstraZeneca will continue to manufacture and supply Crestor to Grünenthal during a transition period and will also continue selling the medicine in other countries, including those in North America, in Japan, China and other emerging markets. 

"This agreement supports the management of our mature medicines to enable reinvestment into the pipeline and bringing new, innovative treatments to patients,” said Ruud Dobber, Executive Vice President at the pharma giant’s BioPharmaceuticals Business Unit, in a statement. 

“Grünenthal previously acquired the rights to several established AstraZeneca medicines and is well placed to ensure continued access to Crestor for patients across Europe." 

Shares rose 2% to 7,932p on Tuesday morning.

--Adds shares--

Quick facts: AstraZeneca

Price: 7592 GBX

LSE:AZN
Market: LSE
Market Cap: £99.91 billion
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Shield Therapeutics remain optimistic about US commercialisation of Accrufer...

Shield Therapeutics PLC (LON:STX) Chief Executive Tim Watts joins Proactive London's Katie Pilbeam to discuss their financial and operational update. Watts highlights the European sales volumes of its breakthrough iron deficiency drug Feraccru which grew by 70% year-on-year. He...

4 hours, 32 minutes ago

2 min read